Post-Stroke Improvement of Motor Function
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- NIHSS differential
研究概览
简要总结
Open-label clinical study where all new patients presenting with cerebrovascular accidents and consenting to treatment are given intravenously a new combination of medications. Patients are evaluated neurologically with NIHSS scores before treatment administration and at 1 month after the first treatment. Further evaluations at 6 months after treatment by NIHSS and Barthel scores are ongoing
详细描述
Patients with cerebrovascular accidents (CVA), ischemic (including those with hemorrhagic transformation), are given a new combination of medications which aims to improve neuronal survival, stimulate mitochondrial genesis and the formation of new synapses. This combination is given as an intravenous perfusion with a 2-hr duration and consists of vitamins B1, B6, B12, C, Actovegin, etc.
Before treatment a NIHSS score is given. Each patient receives 3-4 such perfusions in 1 month and afterwards another NIHSS score is obtained.
Patients are monitored afterwards and those who show improvements receive more such treatments, and new NIHSS and Barthel scores are obtained.
Patients are grouped on the basis of the time interval between CVA occurence and first treatment:
- Group 1: 0-35 days
- Group 2: 36-100 days
- Group 3: 101-360 days Improvement of motor function is compared using NIHSS scores between groups, and between literature and groups
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adults with CVA
- •agreeing to treatment in person or by proxy signing of Informed Consent Form
- •available for NIHSS evaluation
排除标准
- •allergy to any of the substances administered
- •scheduled for surgery or other procedures
- •not available for NIHSS evaluation after at least 48 hours from treatment
研究组 & 干预措施
New Medication Combination
Intervention: Combination Product: Perfusion with New Combination Medication Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
干预措施: Perfusion with New Combination Medication (Combination Product)
结局指标
主要结局
NIHSS differential
时间窗: 1 month after first administration of the combination
score differential on the National Institutes of Health Stroke Scale(NIHSS); total score is evaluated before treatment and 1 month after first treatment; NIHSS scores range between 0 (best score) and 42 (worst score); the differential quantifies an improvement in neurological function
次要结局
未报告次要终点